Archived rilpivirine-associated resistance mutations among ART-naive and virologically suppressed people living with HIV-1 subtype C in Botswana: implications for cabotegravir/rilpivirine use.

MLA

Maruapula, Dorcas, et al. “Archived Rilpivirine-Associated Resistance Mutations among ART-Naive and Virologically Suppressed People Living with HIV-1 Subtype C in Botswana: Implications for Cabotegravir/Rilpivirine Use.” The Journal of Antimicrobial Chemotherapy, vol. 78, no. 10, Oct. 2023, pp. 2489–95. EBSCOhost, https://doi.org/10.1093/jac/dkad258.

APA

Maruapula, D., Moraka, N. O., Bareng, O. T., Mokgethi, P. T., Choga, W. T., Seatla, K. K., Kelentse, N., Koofhethille, C. K., Zuze, B. J. L., Gaolathe, T., Pretorius-Holme, M., Makhema, J., Novitsky, V., Shapiro, R., Moyo, S., Lockman, S., & Gaseitsiwe, S. (2023). Archived rilpivirine-associated resistance mutations among ART-naive and virologically suppressed people living with HIV-1 subtype C in Botswana: implications for cabotegravir/rilpivirine use. The Journal of Antimicrobial Chemotherapy, 78(10), 2489–2495. https://doi.org/10.1093/jac/dkad258

Chicago

Maruapula, Dorcas, Natasha O Moraka, Ontlametse T Bareng, Patrick T Mokgethi, Wonderful T Choga, Kaelo K Seatla, Nametso Kelentse, et al. 2023. “Archived Rilpivirine-Associated Resistance Mutations among ART-Naive and Virologically Suppressed People Living with HIV-1 Subtype C in Botswana: Implications for Cabotegravir/Rilpivirine Use.” The Journal of Antimicrobial Chemotherapy 78 (10): 2489–95. doi:10.1093/jac/dkad258.